

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2013-01-17** | Period of Report: **2013-01-15**
SEC Accession No. [0001010549-13-000027](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

WOUND MANAGEMENT TECHNOLOGIES, INC.

CIK:[714256](#) | IRS No.: **592220004** | State of Incorpor.: **TX** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: [000-11808](#) | Film No.: **13533988**
SIC: **3842** Orthopedic, prosthetic & surgical appliances & supplies

Mailing Address

*777 MAIN STREET
SUITE 3100
FORT WORTH TX 76102*

Business Address

*777 MAIN STREET
SUITE 3100
FORT WORTH TX 76102
817-820-7080*

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 15, 2013

Wound Management Technologies, Inc.

(Exact name of registrant as specified in its charter)

Texas
(State or other jurisdiction
incorporation)

0-11808
(Commission File
Number)

59-2219994
(IRS Employer
Identification No.)

777 Main Street, Suite 3100, Fort Worth, Texas 76102
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code 817-820-7080

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 Other Events

On January 15, 2013, Wound Management Technologies, Inc. (the “Company”) received a final judgment resolving claims against the Company in the Securities and Exchange Commission’s civil enforcement action against the Company and its former CEO, Scott Haire, based upon actions alleged to have been taken in 2009. The judgment was delivered by the United States District Court for the Southern District of Florida.

Under the judgment, the Company has been permanently enjoined from violations of Section 17(a) of the Securities Act and Section 10(b) of the Securities Exchange Act involving the payment of undisclosed compensation to investment advisors, managers, trustees, or any associated person thereof or the manipulation of the price or volume of any security. The Company must also pay a civil penalty in the amount of \$20,000 within fourteen days of the judgment.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WOUND MANAGEMENT TECHNOLOGIES, INC.

Date: January 16, 2013

By: /s/ Robert Lutz, Jr.
Robert Lutz, Jr., Chief Executive Officer
